Characterization of Anti-HER2 Antibodies Using Advanced Flow Cytometry and BLI Label-Free Detection

Antibody-based therapeutics are helping patients across a wide range of disease areas, from cancer, such as Rituximab treatment of CD20-positive non-Hodgkin's lymphomas, to infectious diseases like SARS-CoV-2 and HIV. Conventional techniques used in antibody discovery workflows are often limited due to low-throughput sample acquisition, large sample volume requirements, and challenges around analyzing complex datasets. The development of novel antibody therapeutics relies on high-throughput technologies with powerful analysis capabilities that can reliably screen and profile drug candidates. This webinar will discuss: - Combining the iQue® Advanced Flow Cytometry and Octet® BLI Label-Free Detection platforms to characterize antibodies during drug discovery - Using the iQue® and associated reagent kits for high-throughput analysis of live-cell antibody binding, competitive binding and Fc function - Determination of ligand and Fc-gamma receptor binding kinetics through robust measurements with the Octet® system